Sp377
BARRETT'S SURVEILLANCE: IS THERE ANYTHING REALLY BETER THAN THE SEATTLE PROTOCAL?
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
A variety of new developments in the realms of screening and surveillance of Barrett's esophagus have occurred in recent years. This session will focus on the current evidence base for risk assessment algorithms to enhance screening uptake, new screening tools and obstacles to implementation. In addition, the area of surveillance remains problematic. this session will look at alternatives to the Seattle protocol in terms of risk assessment and enhanced surveillance. Finally the role of artificial intelligence now and in the future will be addressed.
A variety of new developments in the realms of screening and surveillance of Barrett's esophagus have occurred in recent years. This session will focus on the current evidence base for risk assessment algorithms to enhance screening uptake, new screening tools and obstacles to implementation. In addition, the area of surveillance remains problematic. this session will look at alternatives to the Seattle protocol in terms of risk assessment and enhanced surveillance. Finally the role of artificial intelligence now and in the future will be addressed.
Presenter
Amsterdam UMC
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
STATE OF THE ART IN ENDOSCOIC ERADICATION THERAPY FOR BARRETT'S RELATED NEOPLASIA
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
